🇺🇸 FDA
Pipeline program

ampreloxetine

0169

Phase 3 small_molecule active

Quick answer

ampreloxetine for Symptomatic Neurogenic Orthostatic Hypotension is a Phase 3 program (small_molecule) at Theravance Biopharma with 4 ClinicalTrials.gov record(s).

Program details

Company
Theravance Biopharma
Indication
Symptomatic Neurogenic Orthostatic Hypotension
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials